TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04990284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: 50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA/DDCI
Description: L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
Study: NCT05525585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early HMF
Description: Mom's milk or donor milk will be fortified between postnatal day 4 and 7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed HMF
Description: Mom's milk or donor milk will be fortified between postnatal day 10 and 14
Study: NCT05787561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib (VS-6766)
Description: 3.2 mg PO, twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
Study: NCT06411535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement plus Nutritional counseling
Description: After diagnosis of gingivitis, patients will receive a nutritional counseling focused on ultra-processed foods entails educating individuals about the nutritional content and potential health implications of highly processed food products. They will undergo a session of full-mouth ultrasonic debridement and reinforcment of dietary counseling. Between consecutive time points, patients will receive motivational emails.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: After diagnosis of gingivitis, patients will receive a session of full mouth ultrasonic debridement
Study: NCT06177535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kavalactones
Description: Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
Study: NCT04890886

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG of the fetus and the neonate to look at the cardiac electrical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG of the fetus and the neonate to look at the cardiac electrical activity
Study: NCT06177535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
Study: NCT05924178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise rehablitation
Description: Preoperative exercise rehabilitation in experimental group was performed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine treatment
Description: The control group receives conventional treatment preoperative.
Study: NCT04890886

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG of the fetus and the neonate to look at the cardiac electrical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum blood markers
Description: Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum blood markers
Description: Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum blood markers
Description: Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
Study: NCT05981664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Handed Video Game Controller Adapter
Description: The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
Study: NCT04895735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04890886

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum blood markers
Description: Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
Study: NCT05916976

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac MRI
Description: Multiparametric MRI of the heart
Study: NCT06215690

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurements
Description: Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurements
Description: Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth
Study: NCT05747339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor treatment vaccine injection
Description: Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
Study: NCT04547166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04、
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX04、
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Study: NCT06544837

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Window of Implantation
Description: Determine the subject's window of implantation through testing and adjust the embryo implantation time
Study: NCT05426720

Intervention type: OTHER
Intervention: no intervention
Description: no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
Study: NCT05079009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R pulsatile configuration
Description: Use of the pulsatile extracorporeal blood flow configuration.
Study: NCT04895735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET
Study: NCT05017896

Intervention type: DIAGNOSTIC_TEST
Intervention: Normal CT Renal Perfusion imaging indexes
Description: A CT imaging which indicates the status of renal perfusion is normal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low CT Renal Perfusion imaging indexes
Description: A CT imaging which indicates the status of renal perfusion is low.
Study: NCT06203132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine + tenofovir DF + lamivudine
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir + tenofovir DF + lamivudine or emtricitabine
Description: Oral administration
Study: NCT04811274

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: 2 to 5 ml

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: 2 to 5 ml

Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage fluid collection
Description: 5 to 25 ml

Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage fluid collection
Description: 5 to 25 ml
Study: NCT06585527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS-2021
Description: The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.
Study: NCT06006247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 150 mg
Description: Participants will receive 1 CVN424 tablet (150 mg) per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 matching placebo tablet per day.
Study: NCT04963465

Intervention type: DIAGNOSTIC_TEST
Intervention: Ferning on microscopy
Description: Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes

Intervention type: DIAGNOSTIC_TEST
Intervention: Ferning on microscopy
Description: Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
Study: NCT05982301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
Description: The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
Study: NCT05226858

Intervention type: DIAGNOSTIC_TEST
Intervention: Transesophageal echocardiography (TEE)
Description: Sensitivity and specificity of TEE in identification of BTAI
Study: NCT04687735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention after nerve block
Description: Brachial plexus block + Physical therapy
Study: NCT05517200

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Test for Migraine
Description: Resting EEG, and Visual and Auditory Stimulation
Study: NCT05043688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
Study: NCT05207930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAmified HOme-based COgnitive-Nutrition training (GAHOCON)
Description: A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Centre-based online open-source cognitive games
Description: During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
Study: NCT05856955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Coaching Intervention
Description: The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
Study: NCT06344026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANPD001
Description: Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
Study: NCT03874845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study: NCT05960864

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop

Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop
Study: NCT06344026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Device
Description: A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
Study: NCT06223971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]CPPC Injection
Description: A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]CPPC Injection
Description: A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]
Study: NCT06150716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION356
Description: Administered as intrathecal (IT) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION356
Description: Administered as intrathecal (IT) injection.
Study: NCT06058520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota - lyophilized
Description: Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
Study: NCT06169592

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Related transplantation of the right lobe of the liver
Study: NCT05413564

Intervention type: OTHER
Group type: OTHER
Intervention: optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months
Description: optimized self-exclusion procedure A

Intervention type: OTHER
Group type: OTHER
Intervention: optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months
Description: optimized self-exclusion procedure A
Study: NCT04441320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated metal ureteral stent(CMUS)
Description: Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.

Intervention type: DEVICE
Group type: OTHER
Intervention: Double-J stent(DJS)
Description: Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
Study: NCT06363110

Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Follow clinical practice/administration
Study: NCT05147922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Training with the Neonatal Resuscitation Quality Improvement Cart
Description: The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
Study: NCT05194761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Using normal saline nebulization in neonates postextubation
Study: NCT04709432

Intervention type: PROCEDURE
Intervention: ECMO
Description: ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
Study: NCT06280144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, Live, Nasal, Freeze-dried
Description: The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
Study: NCT05915962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collecting a Nanofat-type microfat autograft
Description: Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris.
Study: NCT05470504

Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: 30 mg subcutaneously every day for 4 weeks.
Study: NCT06280144

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water for inhalation
Description: Sterile water for inhalation
Study: NCT05316155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.
Study: NCT05639816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation group
Description: Normal saline irrigation of common bile duct after complete stone removal
Study: NCT05776641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GENUS
Description: Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS
Description: Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
Study: NCT04806646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.